Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Paxalisib (GDC-0084) in Advanced Breast Cancer. The expected timing is based on the latest available company guidance and may change.
6/5/25- First patient dosed. 7/9/25- Reports early efficacy data from first TNBC patient. 11/18/25:- Reported an initial immune-complete response. 12/10/25:- Presentation at SABCS showed 76% tumor shrinkage and strong CTC, immune improvements. 01/27/26:- Ph1b paxalisib combo in metastatic TNBC shows 2 PRs, 1 complete metabolic response; topline data in Q1 2027. 05/26/26:- Ph1b TNBC trial expanded to 36 patients; additional updates expected throughout 2026-2027.
Verification
Confirm timing and program details against the company announcement or filing.